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Abstract
Background
Higher circulating levels of the branched-chain amino acids (BCAAs; i.e., isoleucine, leu-
cine, and valine) are strongly associated with higher type 2 diabetes risk, but it is not known
whether this association is causal. We undertook large-scale human genetic analyses to
address this question.
Methods and Findings
Genome-wide studies of BCAA levels in 16,596 individuals revealed five genomic regions
associated at genome-wide levels of significance (p < 5 × 10−8). The strongest signal was
21 kb upstream of the PPM1K gene (beta in standard deviations [SDs] of leucine per allele =
0.08, p = 3.9 × 10−25), encoding an activator of the mitochondrial branched-chain alpha-
ketoacid dehydrogenase (BCKD) responsible for the rate-limiting step in BCAA catabolism.
In another analysis, in up to 47,877 cases of type 2 diabetes and 267,694 controls, a geneti-
cally predicted difference of 1 SD in amino acid level was associated with an odds ratio for
type 2 diabetes of 1.44 (95% CI 1.26–1.65, p = 9.5 × 10−8) for isoleucine, 1.85 (95% CI
1.41–2.42, p = 7.3 × 10−6) for leucine, and 1.54 (95% CI 1.28–1.84, p = 4.2 × 10−6) for valine.
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Estimates were highly consistent with those from prospective observational studies of the
association between BCAA levels and incident type 2 diabetes in a meta-analysis of 1,992
cases and 4,319 non-cases. Metabolome-wide association analyses of BCAA-raising
alleles revealed high specificity to the BCAA pathway and an accumulation of metabolites
upstream of branched-chain alpha-ketoacid oxidation, consistent with reduced BCKD activ-
ity. Limitations of this study are that, while the association of genetic variants appeared
highly specific, the possibility of pleiotropic associations cannot be entirely excluded. Similar
to other complex phenotypes, genetic scores used in the study captured a limited proportion
of the heritability in BCAA levels. Therefore, it is possible that only some of the mechanisms
that increase BCAA levels or affect BCAA metabolism are implicated in type 2 diabetes.
Conclusions
Evidence from this large-scale human genetic and metabolomic study is consistent with a
causal role of BCAA metabolism in the aetiology of type 2 diabetes.
Author Summary
Why Was This Study Done?
• Higher circulating levels of isoleucine, leucine, and valine, i.e., the branched-chain
amino acids (BCAAs), are strongly associated with the risk of future type 2 diabetes.
• It is not known if this association reflects a causal relationship.
• It is important to assess the aetiologic nature of this relationship. If it is causal, then
intervening on BCAA levels or metabolism may reduce the risk of diabetes.
What Did the Researchers Do and Find?
• We used a human genetics framework known as “Mendelian randomisation” to
study this question. Mendelian randomisation postulates that if a biomarker is caus-
ally implicated in a disease, then genetic variants specifically associated with that bio-
marker should also be associated with the disease.
• In a meta-analysis of 1,992 incident cases of type 2 diabetes and 4,319 non-cases, we
found strong associations between higher levels of each of the BCAAs and a higher
risk of type 2 diabetes.
• In a genome-wide meta-analysis of 16,596 individuals, we identified five genomic
regions where common genetic variants were associated with BCAA levels.
• In a meta-analysis of genetic association studies including 47,877 cases of type 2 dia-
betes and 267,694 controls, a genetically predicted difference of one standard devia-
tion in amino acid level was associated with an odds ratio of type 2 diabetes of 1.44
(95% confidence interval 1.26–1.65) for isoleucine, 1.85 (1.41–2.42) for leucine, and
1.54 (1.28–1.84) for valine.
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What Do These Findings Mean?
• Evidence from this large-scale human genetic and metabolomic study is consistent
with a causal role of BCAA metabolism in the aetiology of type 2 diabetes.
• Possible limitations of the study included the possibility of non-specific associations
of the genetic variants included in the study (i.e., “pleiotropy”) and the relatively low
proportion of heritability in BCAA levels explained by the identified genetic variants.
Introduction
Early evidence of impaired branched-chain amino acid (BCAA) metabolism in insulin resistance
and obesity dates back to more than 40 years ago [1]. More recently, in investigations of the
human metabolome, multiple research groups have described associations of higher levels of iso-
leucine, leucine, and valine with insulin resistance, obesity [2], and a higher risk of future type 2
diabetes [3]. These associations have since been replicated in several studies [4–6] and are cor-
roborated by a growing body of experimental evidence [2,7–10]. However, it remains unknown
whether BCAA metabolism is causally implicated in type 2 diabetes [7] or whether observational
associations simply reflect reverse causality, whereby differences in BCAA levels are a conse-
quence of pathophysiological processes that precede the development of the disease [11].
Genetic approaches to causality assessment provide an opportunity for rapid and cost-effec-
tive prioritisation of targets for interventional studies [12–20]. Therefore, genetic variants asso-
ciated with BCAA levels can be used to study the aetiologic links of the BCAA metabolic
pathway with type 2 diabetes. A previous smaller-scale investigation that was limited to one
genetic variant associated with 3-methyl-2-oxovalerate, a by-product of BCAA metabolism,
was inconclusive [21].
Therefore, in this study, we used genome-wide association studies (GWASs) coupled with
large-scale metabolomic measurements to investigate the aetiologic relationship between
BCAA metabolism and type 2 diabetes, an issue of high clinical and public health relevance
due to the strength of the associations between BCAA levels and type 2 diabetes [2,3] and the
global burden of this condition [22,23].
Methods
Study Design
We adopted a Mendelian randomisation approach to evaluate possible causal relationships
between BCAA metabolism and type 2 diabetes (Fig 1). Inherited DNA variants are randomly
assigned during meiosis and remain fixed throughout the lifetime. Therefore, they are unlikely
to be affected by disease processes (i.e., reverse causality) and non-genetic confounding. Men-
delian randomisation exploits these properties in order to estimate the relationship of modifi-
able risk factors with disease outcomes without the limitations of traditional observational
epidemiology [12–15]. This approach postulates that if a biomarker is causally implicated in a
disease, then genetic variants associated with that biomarker (but not other disease risk fac-
tors) should be associated with the disease in the direction predicted by observational analyses
[12–15].
Branched Chain Amino Acids and Risk of Type 2 Diabetes
PLOS Medicine | DOI:10.1371/journal.pmed.1002179 November 29, 2016 3 / 22
threshold cycle; GWAS, genome-wide association
study; MSUD, maple syrup urine disease; OGTT,
oral glucose tolerance test; SABRE, Southall And
Brent REvisited Study; SD, standard deviation;
SNP, single nucleotide polymorphism.
Therefore, we conducted meta-analyses of (a) GWASs of plasma levels of isoleucine, leu-
cine, and valine; (b) studies of the associations of BCAA-raising genetic variants with type 2
diabetes; and (c) prospective studies of the associations of baseline isoleucine, leucine, and
valine levels with incident type 2 diabetes.
The investigations described in this study were approved by local ethical committees, and
participants provided their informed consent.
Participating Studies
We performed GWASs of the plasma levels of isoleucine, leucine, and valine in the Fenland
study (n = 9,237; S1 Text; S1 Table). Fenland GWAS results were then meta-analysed with
publicly available results from a meta-analysis of the KORA and TwinsUK studies [24]. The
total sample size of the genome-wide meta-analysis was 16,596 individuals.
We estimated the association with type 2 diabetes of the lead single nucleotide polymor-
phism (SNP) at each BCAA-associated genomic locus. We meta-analysed SNP association
results from the DIAbetes Genetics Replication And Meta-analysis [25] and the EPIC-InterAct
[26], GoDARTs [21], and UK Biobank studies [27] (S1 Text; S2 Table). The total sample size of
this analysis was 47,877 type 2 diabetes cases and 267,694 controls.
We conducted a systematic review of the literature of prospective studies of the association
of BCAA levels and incident type 2 diabetes (S1 Text). The results of five prospective popula-
tion-based studies [3–6] were meta-analysed with the unpublished results of the EPIC-Norfolk
Fig 1. Design of the study. DIAGRAM, DIAbetes Genetics Replication And Meta-analysis.
doi:10.1371/journal.pmed.1002179.g001
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case-cohort study using fixed effect models (S3 Table) [28]. The I-squared statistic was used to
quantify heterogeneity. In the EPIC-Norfolk study, the association of metabolite levels with
incident type 2 diabetes was estimated using multivariable Cox proportional hazards regres-
sion with Prentice weighting and robust standard errors. The total sample size of the observa-
tional analysis was 1,992 incident cases of type 2 diabetes and 4,319 non-cases.
Metabolite Measurements
In the Fenland study, BCAA levels were measured using liquid chromatography coupled with
tandem mass spectrometry (S1 Fig; AbsoluteIDQ p180 Kit, Biocrates Life Sciences [29]). In the
KORA and TwinsUK studies, BCAA levels were measured as part of untargeted metabolomic
measurements using gas chromatography mass spectrometry or ultra-performance liquid
chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) [24]. In the EPIC-
Norfolk study, BCAA levels were measured by UPLC-MS/MS (S1 Fig; DiscoveryHD4 plat-
form, Metabolon [30]). This platform also measured an additional 15 metabolites related to
BCAA metabolism. In the Southall And Brent REvisited Study (SABRE), the levels of BCAAs
were measured by nuclear magnetic resonance at 0 and 120 min during the course of an oral
glucose tolerance test (OGTT) [31,32].
Genome-Wide Association Analyses
Genome-wide association analyses were conducted using SNPTEST v2 [33], and study results
were meta-analysed using METAL [34], which was chosen as the analysis software because
studies included in the meta-analysis were focused on individuals of European ancestry. All
genetic association results are reported per allele and assuming an additive effect. In the meta-
analysis of GWASs of BCAA levels, we meta-analysed Z-scores rather than betas and standard
errors in order to minimise the influence of the different platforms used to measure amino
acid levels in participating studies. The conventional threshold for genome-wide statistical sig-
nificance (p< 5 × 10−8) was used to identify associated loci. The SNP with the lowest p-value
within a 1 million base-pair window was chosen as the lead SNP at a given genomic locus.
Variance Explained and Genetic Correlation Analyses
For each amino acid, we estimated the variance in amino acid level explained by the identified
lead SNPs using linear regression models in the Fenland study. We used the BOLT-REML algo-
rithm of the BOLT-LMM v2.2 software [35] to estimate chip-based heritability. This was esti-
mated directly from variants captured across the genome on the genome-wide genotyping chip.
We also used estimates of family-based genetic heritability from twin studies from Shin and col-
leagues [24]. We calculated the proportion of heritability explained by the lead SNPs by dividing
the explained variance estimates by the familial and chip-based heritability estimates. Using
genome-wide association results and LD score regression [36], we estimated genetic correla-
tions of BCAA levels with type 2 diabetes, continuous glycaemic traits (fasting glucose, fasting
insulin, glucose at 2 h in a 75-g OGTT, HbA1c, HOMA-B, and HOMA-IR), and anthropometric
traits (body mass index [BMI] and waist-to-hip ratio) on the LD Hub platform (http://ldsc.
broadinstitute.org/#; accessed 6 October 2016) [37]. Isoleucine estimates were not generated by
the software due to low levels of genetic heritability estimated by the LD Hub platform.
Mendelian Randomisation Analysis
We estimated the association between a genetically predicted difference of 1 standard devia-
tion (SD) in isoleucine, leucine, or valine plasma level and type 2 diabetes risk. For each of the
Branched Chain Amino Acids and Risk of Type 2 Diabetes
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BCAAs, we constructed weighted genetic risk scores including the lead SNP (independent
genetic variants analysis) or genome-wide significant SNPs in imperfect linkage disequilib-
rium (r2 < 0.8 for all pairwise SNP comparisons; correlated genetic variants analysis) at each
locus identified by the genome-wide meta-analysis for that metabolite. Fenland study weights
were used to scale the effect of each genetic score to 1 SD. We used Fenland study weights as
this was the largest study and we had access to individual-level data, allowing the standardisa-
tion of genetic effect estimates. Lead SNPs (nearest gene) included in the genetic scores used in
the independent variants analysis were as follows: rs7678928 (PPM1K), rs75950518
(DDX19A), rs58101275 (TRMT61A), and rs1420601 (CBLN1) for isoleucine; rs1440581
(PPM1K) for leucine; and rs1440581 (PPM1K) for valine. Analyses of correlated genetic vari-
ants modelled the estimates of 12 SNPs at four loci (PPM1K, DDX19A, TRMT61A, and
CBLN1) for isoleucine, seven SNPs at the PPM1K locus for leucine, and eight SNPs at the
PPM1K locus for valine (details in S1 Text).
We combined estimates of “SNP to metabolite” and “SNP to type 2 diabetes” associations
to calculate estimates of each “genetically predicted metabolite level to type 2 diabetes” associa-
tion [13,14]. Estimates of multiple SNPs contributing to a given genetic score were pooled
using an inverse-variance-weighted method [13,14]. For the analysis of correlated genetic vari-
ants, estimates were pooled with a weighted generalised linear regression method that
accounts for the correlation between genetic variants [13]. The correlation values were
obtained using the SNAP software [38]. Results were scaled to represent the odds ratio [OR]
per 1-SD genetically predicted difference in amino acid level. Given that Mendelian randomi-
sation assumes no pleiotropic effect beyond that on the risk factor of interest (i.e., BCAA lev-
els), we excluded the lead SNP (rs1260326) at the known pleiotropic [39–43] GCKR locus from
the isoleucine genetic score (Section 1 of S2 Text).
In order to assess the specificity of the genetic scores, we performed large-scale association
testing of BCAA-raising alleles with the levels of blood metabolites: 175 metabolites in the Fen-
land study, 453 metabolites in KORA and TwinsUK, and 18 metabolites of the BCAA pathway
in the EPIC-Norfolk study (S1 Text). We also investigated the association of BCAA-raising
alleles with cardiometabolic traits in large-scale GWAS meta-analyses of up to 328,036 individ-
uals [39–43].
Type 2 Diabetes Disease Mechanisms and BCAA Metabolism
We investigated other potential links between BCAA levels and type 2 diabetes. We tested the
association with BCAA levels of a genetic predisposition to higher BMI, greater insulin resis-
tance, and impaired insulin secretion using previously validated unweighted genetic scores for
these traits [44–46] (S4 Table). Using linear regression models, we estimated the association of
fasting insulin with BCAA levels during the course of an OGTT in the SABRE study.
Expression of PPM1K in Muscle Biopsies
We investigated changes in levels of PPM1K gene expression in skeletal muscle during the
course of an OGTT. Fifty age-matched men with either normal glucose tolerance (n = 25) or
type 2 diabetes (n = 25) were recruited at the Karolinska Institutet, Sweden. Following an over-
night fast, a skeletal muscle biopsy was taken from the vastus lateralis muscle under local
anaesthesia with a Weil-Blakesley conchotome tong instrument (Agntho’s). Participants
ingested a standardised solution containing 75 g of glucose, and 2 h later a second biopsy was
taken from the vastus lateralis of the contralateral leg. Biopsies were frozen immediately and
stored in liquid nitrogen until processed. Total RNA was extracted from biopsies using the
mirVana miRNA Isolation Kit (Thermo Fisher). Equal amounts of total RNA were used to
Branched Chain Amino Acids and Risk of Type 2 Diabetes
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synthesize cDNA using random primers and the High Capacity cDNA Reverse Transcription
Kit (Thermo Fisher). Quantitative PCR was performed with a ViiA 7 Real-Time PCR System
with Fast SYBR Green Master Mix (Thermo Fisher). The ViiA 7 Software (version 1.1) was
used to determine threshold cycle (Ct) values, and relative gene expression was calculated with
the comparative Ct method relative to a reference gene, with dCt being the difference in
expression between the gene of interest and the reference gene. The most suitable reference
genes were determined to be GUSB, RPLP0, and TBP (out of four measured genes) using the
NormFinder algorithm (Multid Analyses) [47]. Statistical analysis was performed on dCt val-
ues since these were normally distributed.
Statistical Analysis
Both Mendelian randomisation and observational association estimates are reported per 1-SD
increase in metabolite level. Standardisation was necessary in light of the different platforms
used to measure BCAA levels. Analyses were conducted using STATA v13.1 (StataCorp) and
R (https://cran.r-project.org/). Further details of the methods used in this study are reported in
S1 Text.
Results
Genome-Wide Association Studies of Isoleucine, Leucine, and Valine
Genome-wide meta-analyses of 10.5 million genetic variants in 16,596 individuals revealed
five independent genomic loci associated with BCAA levels at the genome-wide level of statis-
tical significance (Table 1; Figs 2, S2 and S3). The strongest signal was 21 kb upstream of the
PPM1K gene on Chromosome 4q22.1, a locus previously reported for BCAA levels [24,48]
(Fig 2).
PPM1K encodes the mitochondrial phosphatase that activates the branched-chain alpha-
ketoacid dehydrogenase (BCKD) complex [49–51]. This catalytic complex is responsible for
the rate-limiting step of BCAA catabolism, i.e., the irreversible oxidative decarboxylation of
branched-chain alpha-ketoacids [49–51]. In addition to PPM1K, we identified four novel loci
associated with isoleucine (Table 1; Fig 2). Lead SNPs at these loci were also associated with
the levels of the other two BCAAs in a consistent direction, albeit not at the genome-wide level
of significance (S5 Table).
We estimated that identified lead genetic variants explain 7.5%, 6.3%, and 5.3% of the chip-
based heritability of isoleucine, leucine, and valine levels estimated in the Fenland study using
Table 1. Genetic variants associated with the levels of branched-chain amino acids in the genome-wide meta-analysis.





EAF Beta (SE) of
Metabolite Level
per Allele
p-Value Sample Size for Type 2
Diabetes, N Cases/N
Controls




Isoleucine PPM1K rs7678928 4:89222827 T/C 46% 0.09 (0.013) 5.6 × 10−19 25,208/209,575 1.03 (1.01–1.05) 0.0055
GCKR rs1260326 2:27730940 T/C 41% 0.06 (0.012) 1.1 × 10−09 47,877/267,694 0.94 (0.92–0.96) 3.9 × 10−11
DDX19A rs75950518 16:70378917 C/T 89% 0.11 (0.019) 2.1 × 10−08 13,037/152,713 1.05 (1.01–1.10) 0.016
TRMT61A rs58101275 14:104008420 G/A 79% 0.09 (0.015) 2.8 × 10−08 13,037/152,713 1.04 (1.01–1.08) 0.012
CBLN1 rs1420601 16:49085649 C/T 40% 0.07 (0.013) 3.7 × 10−08 13,037/152,713 1.01 (0.98–1.04) 0.53
Leucine PPM1K rs1440581 4:89226422 C/T 53% 0.08 (0.013) 3.9 × 10−25 30,169/215,523 1.04 (1.02–1.07) 0.00034
Valine PPM1K rs1440581 4:89226422 C/T 53% 0.10 (0.013) 4.4 × 10−24 30,169/215,523 1.04 (1.02–1.07) 0.00034
Genomic coordinates are relative to human genome reference sequence hg19. Beta coefficients are in standardised units.
EAF, effect allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism; SE, standard error.
doi:10.1371/journal.pmed.1002179.t001
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BOLT-LMM [35] and 2.2%, 0.8%, and 1.2% of the family-based heritability of isoleucine, leu-
cine, and valine levels estimated in twin studies [24], respectively.
Fig 2. Manhattan plot of the association of genetic variants with the levels of branched-chain amino acids.
doi:10.1371/journal.pmed.1002179.g002
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Association of BCAA-Raising Alleles with Type 2 Diabetes
A genetic predisposition to a higher level of isoleucine, leucine, or valine was strongly asso-
ciated with higher odds for type 2 diabetes (for isoleucine, OR 1.44, 95% CI 1.26–1.65,
p = 9.5 × 10−8; for leucine, OR 1.85, 95% CI 1.41–2.42, p = 7.3 × 10−6; for valine, OR 1.54, 95%
CI 1.28–1.84, p = 4.2 × 10−6; Fig 3A). Relative risk estimates from genetic analyses based on the
identified genetic variants were similar to those from the prospective studies of the association
between baseline amino acid levels and incident type 2 diabetes (Figs 3A, S4 and S5; Section 2
of S2 Text). For isoleucine, the results of the genetic analyses were almost identical when con-
sidering genetic variants at the PPM1K locus only or genetic variants at all four loci (S6 Table).
At the PPM1K locus, both the lead SNPs in the BCAA association analyses, rs1440581 (r2 =
0.88) and rs7678928 (r2 = 0.70), were in linkage disequilibrium with the lead type 2 diabetes
SNP at the locus, rs1975393 (Fig 3B). There was a dose-response relationship between the asso-
ciation with amino acid level and the relative increase in diabetes risk for the four lead SNPs
that were used for the construction of the isoleucine genetic score (Fig 3C). Similarly, the asso-
ciation between isoleucine level and incident type 2 diabetes in prospective studies showed a
graded dose-response relationship (Fig 3D; S7 Table).
BCAA-Raising Alleles, Continuous Metabolic Traits, and Plasma
Metabolites
The isoleucine, leucine, and valine genetic scores were specifically associated with the three
BCAAs and not with any of the remaining 172 metabolites measured in the Fenland study (Fig
4). Consistent with these results, the rs1440581 SNP at PPM1K was associated with only eight
out of 453 metabolites studied by Shin et al. [24], all of which belonged to the BCAA pathway (S8
Table). These results illustrate the high specificity to BCAA metabolism of these genetic scores.
The BCAA-raising genetic scores and their constituent SNPs were not associated with con-
tinuous metabolic traits in large-scale meta-analyses. There was an association of the isoleu-
cine-raising allele of rs1420601 near CBLN1 with higher BMI (S9 Table), but this did not affect
the main analysis results (OR for type 2 diabetes after exclusion of rs1420601 = 1.50, 95% CI
1.25–1.80, p = 0.000013).
We assessed genome-wide genetic correlations of BCAA levels with type 2 diabetes and
continuous metabolic traits and found statistically significant (p< 0.05) positive correlations
of (a) leucine level with type 2 diabetes (rgenetic = 0.34, p = 0.0004), HbA1c (rgenetic = 0.34,
p = 0.0038), BMI (rgenetic = 0.25, p = 1.5 × 10−5), and waist-to-hip ratio (rgenetic = 0.29, p =
2.6 × 10−6) and of (b) valine level with type 2 diabetes (rgenetic = 0.54, p = 8.8 × 10−5), fasting
insulin (rgenetic = 0.42, p = 0.013), BMI (rgenetic = 0.43, p = 1.8 × 10−5), waist-to-hip ratio
(rgenetic = 0.47, p = 6.4 × 10−6), HOMA-B (rgenetic = 0.40, p = 0.016), and HOMA-IR (rgenetic =
0.45, p = 0.012).
Type 2 Diabetes Disease Mechanisms and BCAA Metabolism
In the Fenland study, both higher BMI and higher fasting insulin level, a measure of fasting-
state insulin resistance, were associated with higher levels of BCAAs (S10 Table). In addition,
genetic predispositions to higher BMI and insulin resistance, but not to impaired insulin secre-
tion, were associated with higher levels of BCAAs (S11 and S12 Tables; S6 Fig). The association
of genetic predisposition to greater adiposity with high BCAA levels appeared to be mediated
by insulin resistance (S11 Table). In the SABRE study, a glucose challenge resulted in a reduc-
tion of circulating BCAA levels. Individuals with higher fasting insulin showed a diminished
reduction of all three BCAA levels in response to a glucose challenge (S7 Fig; S13 and S14
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Tables). In muscle biopsies collected during an oral glucose challenge, the expression of
PPM1K increased at 2 h in normoglycaemic individuals, but not in age-matched patients with
type 2 diabetes (S8 Fig). These results are in line with what has been reported in previous
investigations [52,53] and suggest that greater adiposity and impaired insulin sensitivity result
in exposure to higher levels of BCAAs both in the fasting state and after glucose intake, which
could be mediated at least in part by impaired BCKD activation.
BCAA Pathway Analysis
Because BCAA-raising alleles were strongly associated with metabolites specific to the BCAA
pathway, we hypothesized that studying their pattern of association might provide additional
insights into the mechanisms affected by these genetic variants. Using untargeted metabolo-
mics in up to 8,693 individuals, we investigated the association of BCAA-raising alleles with
the levels of 18 metabolites involved in BCAA metabolism (Tables 2 and S15; Fig 5). BCAA-
raising genetic variants were strongly associated with higher levels of the branched-chain
alpha-ketoacids and other metabolites upstream of the irreversible branched-chain alpha-
ketoacid dehydrogenation (Fig 5). Metabolites downstream of this important biochemical
reaction were largely unaffected by BCAA-raising alleles (Tables 2 and S15; Fig 5).
Higher levels of branched-chain alpha-ketoacids and other metabolites upstream of BCKD
action were also strongly associated with a higher risk of incident type 2 diabetes in the EPIC-
Norfolk case-cohort study, whereas the associations of downstream metabolites were inconsis-
tent (Tables 2 and S15; Fig 5).
Discussion
In this large-scale human genetic study, BCAA-raising polymorphisms identified with a
genome-wide approach were associated with a higher risk of type 2 diabetes. Our findings sug-
gest that mechanisms leading to impaired BCAA metabolism are implicated in the pathophysi-
ology of type 2 diabetes. Given the strong and specific association with the BCAA pathway
observed after testing more than 500 metabolic phenotypes, it is unlikely that the identified
genetic variants affect type 2 diabetes risk via mechanisms outside of this metabolic pathway.
The relative increase in diabetes risk associated with these genetic variants appeared to be pro-
portional to the size of the association with amino acid levels, which would further support a
possible causal link. The diabetes risk increase estimated in genetic analyses was also consistent
with the direction and magnitude of association between baseline amino acid levels and inci-
dent diabetes in observational prospective studies.
Fig 3. Genetically predicted or measured levels of the branched-chain amino acids and risk of type 2
diabetes. (A) Comparison of (i) the association of a difference of 1 SD in the levels of BCAAs at baseline with incident
type 2 diabetes in prospective observational studies (bars with blue circles) and (ii) the association of a genetically
predicted difference of 1 SD in BCAA levels with type 2 diabetes in genetic Mendelian randomisation studies (bars with
red squares for analyses of independent genetic variants and bars with orange diamonds for analyses of correlated
genetic variants). (B) Regional association plots for the association of variants at the PPM1K locus with valine (top;
representative of the three BCAAs) and type 2 diabetes (bottom). Associations were characterised by a peak of signal
upstream of the PPM1K gene, with the lead rs1440581 polymorphism and other polymorphisms in high linkage
disequilibrium, as well as a peripheral signal overlaying the gene, with variants in lower linkage disequilibrium with the
lead polymorphism. (C) Scatter plot of the association of the isoleucine-raising alleles included in the isoleucine
genetic score with amino acid levels and with type 2 diabetes risk. (D) The association of the quartiles of isoleucine
level at baseline with incident type 2 diabetes in the EPIC-Norfolk case-cohort study, the Framingham Offspring Study,
and the Malmo¨ Diet and Cancer Study (1,025 cases of incident type 2 diabetes and 1,182 controls). Error bars
represent the 95% confidence intervals around the central estimates. BCAA, branched-chain amino acid; OR, odds
ratio; RR, relative risk; SD, standard deviation; T2D, type 2 diabetes.
doi:10.1371/journal.pmed.1002179.g003
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A genetic predisposition to insulin resistance was associated with higher plasma BCAA lev-
els, suggesting that previously reported associations between genetic susceptibility to higher
BMI and BCAA levels [11] may be mediated by insulin resistance mechanisms. Consistent
with recent studies in mice [54], the expression of PPM1K in muscle biopsies during an oral
glucose challenge failed to increase in people with type 2 diabetes, suggesting that the link
between insulin resistance and higher BCAA levels may be partly mediated by impaired
Fig 4. Association of branched-chain amino acid genetic scores with metabolites in the Fenland study. Associations of the BCAA scores with the
BCAAs are highlighted in dark red. Error bars represent the 95% confidence interval around the central estimate.BCAA, branched-chain amino acid; SD,
standard deviation.
doi:10.1371/journal.pmed.1002179.g004
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BCKD activation. Therefore, part of the contribution of insulin resistance mechanisms to type
2 diabetes may be exerted via impaired BCAA metabolism.
In metabolome-wide investigations of BCAA-raising alleles, we found evidence of an accu-
mulation of BCAAs and BCAA-derived metabolites upstream of the oxidative dehydrogena-
tion of branched-chain alpha-ketoacids. This reaction is the irreversible and rate-limiting step
in BCAA metabolism, catalysed by the mitochondrial BCKD complex [55]. The pattern of
association observed in this study mirrors that observed in maple syrup urine disease
(MSUD), an inborn error of metabolism caused by rare loss-of-function mutations in genes
encoding components of the BCKD complex [55] or its regulatory phosphatase [56]. In our
GWAS of BCAA levels, the strongest association signal was located 21 kb upstream of the
PPM1K gene, which encodes the mitochondrial phosphatase that activates BCKD [49–51].
Loss-of-function mutations of PPM1K in humans [56] or the knock-out of its ortholog Ppm1k
in mice models [35] results in impaired BCKD activity and high levels of BCAAs and
branched-chain alpha-ketoacids, a pattern that resembles that observed for common PPM1K
genetic variants in our study. Therefore, it is plausible that the genetic variants identified in
this study act by impairing the catabolism of BCAAs, hence leading to higher circulating levels
of these amino acids. We found that levels of all metabolites accumulated upstream of BCKD
action were associated with incident type 2 diabetes. This further supports the hypothesis that
reduced BCKD activity could be one of the mechanistic links between BCAA metabolism and
type 2 diabetes.
Our findings have public health and clinical implications as they indicate that modulation
of BCAA metabolism may impact diabetes risk. The activity of BCKD is a major determinant
Table 2. BCAA pathway associations.
Position in the
BCAA Pathway
Category Metabolite Beta (SE) for Metabolite
per rs1440581-C Allele
p-Value RR (95% CI) of Type 2 Diabetes
per 1-SD Increase in Metabolite
Level
p-Value
Upstream of BCKD BCAA Isoleucine 0.09 (0.02) 6.0 × 10−8 1.31 (1.11–1.54) 0.0012
Leucine 0.11 (0.01) 8.2 × 10−19 1.22 (1.03–1.43) 0.018
Valine 0.12 (0.02) 4.6 × 10−12 1.34 (1.12–1.61) 0.0013
BCKA 3-methyl-2-oxovalerate 0.13 (0.01) 1.5 × 10−19 1.62 (1.35–1.95) 3.1 × 10−7
3-methyl-2-oxobutyrate 0.13 (0.02) 3.3 × 10−14 1.60 (1.33–1.92) 5.8 × 10−7
3-hydroxy-
2-ethylpropionate





0.11 (0.04) 0.0042 1.36 (1.18–1.58) 3.4 × 10−5
Alpha-
hydroxyisovalerate
0.09 (0.02) 8.8 × 10−9 1.22 (1.05–1.41) 0.0098
Alpha-
hydroxyisocaproate
0.12 (0.04) 0.00066 1.22 (1.03–1.45) 0.025
Downstream of
BCKD
Other 3-hydroxyisobutyrate 0.01 (0.04) 0.71 1.32 (1.13–1.54) 0.00047
Acylcarnitine Propionylcarnitine −0.04 (0.02) 0.010 1.15 (0.98–1.34) 0.078
Isovalerylcarnitine −0.01 (0.02) 0.42 1.13 (0.97–1.32) 0.11
Isobutyrylcarnitine 0.02 (0.02) 0.13 0.82 (0.70–0.96) 0.014
The table reports the association of a genetic predisposition to higher BCAA levels with the levels of other metabolites in the BCAA pathway. The table also
reports the association of higher levels of metabolites in the BCAA pathway with the risk of incident type 2 diabetes. Beta coefficients are in standardised
units.
BCAA, branched-chain amino acid; BCKA, branched-chain alpha-ketoacid; BCKD, branched-chain alpha-ketoacid dehydrogenase; RR, relative risk; SE,
standard error; SD, standard deviation.
doi:10.1371/journal.pmed.1002179.t002
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of the rate of BCAA catabolism and is amenable to modulation by pharmacological interven-
tion [57–62]. Improving insulin sensitivity may also ameliorate BCAA metabolism, resulting
in reduced diabetes risk. This approach is supported by the well-described reduction of amino
acid levels following the administration or secretion of insulin [63,64], by our finding of higher
BCAA levels in individuals with a genetic predisposition to insulin resistance, and by the
observation of reduced BCAA levels following insulin-sensitising interventions [65–67].
Future studies will clarify the molecular mechanisms linking impaired BCAA metabolism
and increased risk of type 2 diabetes. The lack of a strong association between BCAA-raising
alleles and continuous metabolic traits in publicly available GWAS meta-analyses possibly
reflects a lack of statistical power or the unavailability of data about specific glycaemic traits
altered by these alleles, similar to several other type 2 diabetes risk variants [25]. We found pos-
itive genetic correlations of BCAA levels with type 2 diabetes and several glycaemic and
anthropometric traits, which points to shared genetic determinants between BCAA levels and
greater adiposity, hyperinsulinaemia, and hyperglycaemia.
A growing body of evidence from human, cellular, and animal models is beginning to shed
light on the possible mechanisms linking BCAA metabolism and diabetes risk [2,7,8,68].
Emerging mechanistic explanations include a synergistic interference of BCAAs and lipids
Fig 5. Schematic representation of the branched-chain amino acid pathway and associations with type 2 diabetes. BCKD, branched-chain alpha-
ketoacid dehydrogenase.
doi:10.1371/journal.pmed.1002179.g005
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with the response of peripheral tissues to insulin [8]. In animal feeding studies, BCAA supple-
mentation requires the background of a high-fat diet to promote insulin resistance [8]. The
rs1440581-C variant, i.e., the lead BCAA-raising allele in our genome-wide association analy-
sis, was found to be associated with less weight loss and insulin sensitisation following a calo-
rie-restricted, high-fat diet in a dietary intervention study in humans [69]. Recent research has
shown that higher BCAA levels are associated with a gut microbiome pattern characterised by
enriched BCAA biosynthetic potential, including Prevotella copri and Bacteroides vulgatus spe-
cies, pointing to a possible role of the gut flora in the relationship between BCAA levels and
insulin resistance [70]. BCAAs and their by-products have also been linked to beta-cell dys-
function [7–9]. The knock-down of PPM1K in clonal INS-1 cell lines has been shown to impair
glucose-stimulated insulin secretion [9]. It has also been suggested that a chronic exposure to
high levels of BCAAs may result in a constant hyperinsulinaemic response, eventually leading
to beta-cell exhaustion [8]. The increased oxidative stress associated with the accumulation of
BCAA-derived alpha-ketoacids is consistent with the link between superoxide generation and
beta-cell dysfunction [71,72].
Another aspect to be elucidated is whether patients with MSUD have altered glycaemic
metabolism. Alterations of glucose metabolism were not reported as a clinical feature in a
review of the phenotype of the disease [55]. However, Mogos et al. reported hypoglycaemia in
a case of MSUD, which could perhaps be consistent with the hypothesis of BCAA-mediated
hyperinsulinaemia [73]. MSUD can be fatal early in life, is often associated with severe cogni-
tive impairment, and is managed with a tightly controlled therapeutic diet [55]. Therefore,
MSUD may not be an optimal model to study the risk of a late-life disease with important die-
tary determinants such as type 2 diabetes.
Limitations of the genetic approach used in this study affect its interpretation. Mendelian
randomisation assumes that the genetic variants used as instruments are associated with the dis-
ease exclusively via the risk factor of interest. For this reason, we excluded the pleiotropic GCKR
locus from analysis. We also assessed the association of genetic variants with more than 500 phe-
notypes, without finding evidence of pleiotropy. While this reduces the possibility that pleiotropy
has influenced our findings, we cannot entirely exclude the possibility of pleiotropic associations.
Similar to other complex traits, the genetic variants identified in this study explain only a fraction
of the heritability of BCAA levels. Therefore, it is possible that only some of the mechanisms that
increase BCAA levels or affect their metabolism are implicated in type 2 diabetes.
While our genetic approach investigated the relationships between circulating BCAA
levels and diabetes risk, BCAA metabolism is a complex biological phenomenon closely linked
to other metabolic pathways. It is plausible that changes in this metabolic pathway may influ-
ence diabetes risk only in a certain metabolic context. Some suggestions come from the emerg-
ing biology of the glucokinase regulatory protein (GCKR), the genetic variants of which had to
be excluded from our study for methodological reasons. GCKR is known to switch liver
metabolism from production of glucose towards that of triglycerides, in particular triglycerides
with lower carbon content and double bonds [74,75]. These lipid species are associated with
higher diabetes incidence in observational studies [76]. Therefore, the activation of specific
pathways (such as those that increase circulating BCAAs or short-chain, highly saturated tri-
glycerides) may typically increase type 2 diabetes risk, except when such activation is caused
by GCKR. These findings suggest that (a) the mechanisms by which the concentrations of
these biomarkers are raised, not their higher concentrations per se, are implicated in higher
metabolic risk and (b) higher BCAA levels might be tolerated as long as other protective path-
ways are activated. Larger-scale genetic studies and randomised controlled trials will help to
further qualify the causal nature of the relationship between BCAA metabolism and type 2 dia-
betes risk.
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Conclusions
In this study, BCAA-raising polymorphisms identified with a genome-wide approach were
associated with a higher risk of type 2 diabetes, consistent with a causal role of BCAA metabo-
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